Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM.
It is estimated that pharmaceutical sales within the MDD market were approximately $3.2 Billion in 2015 across the 7MM. The US contributed 76.1% of these sales, generating an estimated $2.4 Billion. The large US share was predominantly due to sales from the atypical antipsychotics, such as Otsuka/BMS’ Abilify and AstraZeneca’s Seroquel XR, which have higher costs of therapy compared with other marketed antidepressants.
By the end of the forecast period in 2025, MDD sales in the 7MM are expected to grow to $5.8 Billion at a Compound Annual Growth Rate (CAGR) of 6.1% over the 10-year period. The majority of this growth is attributed to sales from the atypical antipsychotics, such as Otsuka/BMS’ Abilify, AstraZeneca’s Seroquel XR, and Otsuka/Lundbeck’s Rexulti, which are expected to collectively capture 38.9% of the global market in 2025, and generate $2.2 Billion in sales.
According to Christos Michaelides, Analyst: “Atypical antipsychotics such as Otsuka/Bristol-Myers Squibb’s Abilify, AstraZeneca’s Seroquel XR, and Otsuka/Lundbeck’s Rexulti are expected to collectively capture approximately 39% of the global market in 2025, and generate an impressive $2.2 Billion in sales. Although Abilify and Seroquel will experience some generic erosion over the forecast period, Rexulti will continue to drive sales upwards following its expected launches in the US and Europe in 2018.
The major drivers of growth of the MDD market during the forecast period include:
The growth of the atypical antipsychotics throughout the 7MM, most notably from Otsuka/Lundbeck’s Rexulti.
The increasing global diagnosed prevalence of MDD, due to increased public awareness and routine screening for depressive disorders, as well as an increase in socioeconomic stress.
The potential introduction of six late-stage pipeline products into the MDD market, some of which have novel mechanisms of action (MOAs), such as Janssen’s esketamine, Alkermes’ ALKS-5461, and Allergan’s rapastinel.
The report “PharmaPoint: Major Depressive Disorder – Global Drug Forecast and Market Assessment to 2025” overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
In particular, this report provides the following analysis:
Annualized MDD market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MDD therapeutics market.
Pipeline analysis: focus on eight late-stage pipeline MDD drugs, discussing emerging trends as well as an overview of earlier phase drugs.
Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: AbbVie, Abbott Laboratories, Abbott Laboratories, Alkermes, Allergan, Asahi Kasei, Astellas, AstraZeneca, Avanir Pharmaceuticals, Axsome Therapeutics, Bristol-Myers Squibb, e-Therapeutics, Eli Lilly, GlaxoSmithKline, Gedeon Richter, Janssen, Lundbeck, Meiji Seika, Merck & Co., Methylation Sciences, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Mochida, Moksha8, Neuralstem Pharmaceuticals, Novartis, Otsuka, Pfizer, Pierre Fabre, Royalty Pharma, Sandoz, Shionogi, Takeda, Teva Pharmaceutical.